Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Chunmei Yang, Tingwan Du, Yueying Zhao, Youhui Qian, Jiashi Tang, Xiaohong Li & Ling Ma. (2024) Development and Validation of a Risk Prediction Model for NAFLD: A Study Based on a Physical Examination Population. Diabetes, Metabolic Syndrome and Obesity 17, pages 143-155.
Read now
Read now
Jingquan Ji, Ming Feng, Yan Huang & Xiaohong Niu. (2022) Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. Bioengineered 13:3, pages 5091-5102.
Read now
Read now
Articles from other publishers (16)
Tianqi Cai, Xinhua Song, Xiaoxue Xu, Ling Dong, Shufei Liang, Meiling Xin, Yuhong Huang, Linghui Zhu, Tianxing Li, Xueke Wang, Yini Fang, Zhengbao Xu, Chao Wang, Meng Wang, Jingda Li, Yanfei Zheng, Wenlong Sun & Lingru Li. (2024) Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota. Frontiers in Cellular and Infection Microbiology 14.
Crossref
Crossref
John M. Flack, Michael G. Buhnerkempe & Kenneth Todd Moore. (2024) Resistant Hypertension: Disease Burden and Emerging Treatment Options. Current Hypertension Reports.
Crossref
Crossref
Qing Lv, Qianqian Han, Ziyun Wen, Yunyun PanJisheng Chen. (2024) The association between atherosclerosis and nonalcoholic fatty liver disease. Medicine 103:1, pages e36815.
Crossref
Crossref
Sufei Song, Jixian Zheng, Dongmei Zhao, Anni Zheng, Ye Zhu, Qiuling Xu & Tao Liu. (2023) Quantitative proteomics analysis based on data-independent acquisition reveals the effect of Shenling Baizhu powder (SLP) on protein expression in MAFLD rat liver tissue. Clinical Proteomics 20:1.
Crossref
Crossref
Navya Malladi, Md Jahangir Alam, Subir K. Maulik & Sanjay K. Banerjee. (2023) The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics. Prostaglandins & Other Lipid Mediators 169, pages 106766.
Crossref
Crossref
Serena Martinelli, Giulia Nannini, Fabio Cianchi, Fabio Staderini, Francesco Coratti & Amedeo Amedei. (2023) Microbiota Transplant and Gynecological Disorders: The Bridge between Present and Future Treatments. Microorganisms 11:10, pages 2407.
Crossref
Crossref
Julia A. Golubeva, Anna F. Sheptulina, Anastasia Yu. Elkina, Ekaterina O. Liusina, Anton R. Kiselev & Oxana M. Drapkina. (2023) Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?. Biomedicines 11:9, pages 2465.
Crossref
Crossref
Yoonmi Park, Stephanie A. Smith-Warner, Xuehong Zhang, Yoon Jung Park, Hyesook Kim, Hyesook Park, Hye Ah Lee & Seungyoun Jung. (2023) Association between use of vitamin and mineral supplement and non-alcoholic fatty liver disease in hypertensive adults. Scientific Reports 13:1.
Crossref
Crossref
Amirhossein Naghipour, Ehsan Amini-Salehi, Mahdi Orang Gorabzarmakhi, Milad Shahdkar, Bahman Fouladi, Iraj Alipourfard & Zahra Momayez Sanat. (2023) Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study. Systematic Reviews 12:1.
Crossref
Crossref
Gourdas Choudhuri, Saumin Shah, Anand Kulkarni, Nitin Jagtap, Pratyusha Gaonkar, Akshay Desai & Charles Adhav. (2023) Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions. Cureus.
Crossref
Crossref
Olufunto O. Badmus, Terry D. HindsJrJr & David E. Stec. (2023) Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease. Current Hypertension Reports 25:8, pages 151-162.
Crossref
Crossref
Mahmoud A. Shatta, Marwa O. El-Derany, Abdullah A. Gibriel & Hala O. El-Mesallamy. (2022) Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro. Molecular and Cellular Biochemistry 478:8, pages 1689-1704.
Crossref
Crossref
Sayuri Yoshikawa, Kurumi Taniguchi, Haruka Sawamura, Yuka Ikeda, Tomoko Asai, Ai Tsuji & Satoru Matsuda. (2023) Metabolic Associated Fatty Liver Disease as a Risk Factor for the Development of Central Nervous System Disorders. Livers 3:1, pages 21-32.
Crossref
Crossref
Qirui Song, Qianhui Ling, Luyun Fan, Yue Deng, Qiannan Gao, Ruixue Yang, Shuohua Chen, Shouling Wu & Jun Cai. (2023) Severity of non-alcoholic fatty liver disease is a risk factor for developing hypertension from prehypertension. Chinese Medical Journal Publish Ahead of Print.
Crossref
Crossref
Yanqi Lan, Ying Lu, Jinfeng Li, Shiqi Hu, Shuohua Chen, Yanhong Wang, Xiaojie Yuan, Hongmin Liu, Xiaomo Wang, Shouling Wu & Li Wang. (2022) Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China. Hepatology Communications 6:12, pages 3393-3405.
Crossref
Crossref
Yu Zhu, Hu Yang, Shaoxian Liang, Honghua Zhang, Yufeng Mo, Songxian Rao, Yaozong Zhang, Zhuang Zhang, Weiqiang Wang & Wanshui Yang. (2022) Higher Adherence to Healthy Lifestyle Score Is Associated with Lower Odds of Non-Alcoholic Fatty Liver Disease. Nutrients 14:21, pages 4462.
Crossref
Crossref